

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5096181

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the PATENT NUMBER 7541537 AND REPLACE IT WITH 7541357 previously recorded on Reel 034045 Frame 0951. Assignor(s) hereby confirms the SECURITY INTEREST.
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ALBANY MOLECULAR RESEARCH, INC.	10/24/2014
ALO ACQUISITION LLC	10/24/2014
AMRI BURLINGTON, INC.	10/24/2014
AMRI RENSSELAER, INC.	10/24/2014
CEDARBURG PHARMACEUTICALS, INC.	10/24/2014
OSO BIOPHARMACEUTICALS MANUFACTURING, LLC	10/24/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
<b>Street Address:</b>	745 7TH AVENUE
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019
<b>PROPERTY NUMBERS Total: 103</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7238704
Patent Number:	7745619
Patent Number:	8053428
Patent Number:	7842802
Patent Number:	7235564
Patent Number:	7956050
Patent Number:	8039453
Patent Number:	8791101
Patent Number:	8106244
Patent Number:	8575186
Patent Number:	8268868
Patent Number:	7863271
Patent Number:	8716308
Patent Number:	8101632

PATENT

Property Type	Number
Patent Number:	8124600
Patent Number:	8501729
Patent Number:	8710047
Patent Number:	7307094
Patent Number:	7781430
Patent Number:	8754054
Patent Number:	8697700
Patent Number:	6949559
Patent Number:	6747039
Patent Number:	7538084
Patent Number:	7084152
Patent Number:	6579885
Patent Number:	7612090
Patent Number:	7265116
Patent Number:	7419985
Patent Number:	7309789
Patent Number:	7541357
Patent Number:	7799756
Patent Number:	7511013
Patent Number:	7378391
Patent Number:	7361636
Patent Number:	7632807
Patent Number:	8227486
Patent Number:	8236796
Patent Number:	8445494
Patent Number:	8420811
Patent Number:	5750703
Patent Number:	6444824
Patent Number:	6458958
Patent Number:	6919458
Patent Number:	7678915
Patent Number:	8476445
Patent Number:	6201124
Patent Number:	6452011
Patent Number:	6448406
Patent Number:	6974872
Patent Number:	7560561
Patent Number:	8022220

Property Type	Number
Patent Number:	6613907
Patent Number:	7232908
Patent Number:	7691615
Patent Number:	7863452
Patent Number:	8067605
Patent Number:	7858798
Patent Number:	8067604
Patent Number:	8178666
Patent Number:	6797826
Patent Number:	7238834
Patent Number:	7390906
Patent Number:	5578610
Patent Number:	5581011
Patent Number:	5589487
Patent Number:	5994549
Patent Number:	5663412
Patent Number:	6153754
Patent Number:	7163949
Patent Number:	7321064
Patent Number:	8183401
Patent Number:	8541609
Patent Number:	8110681
Patent Number:	8273770
Patent Number:	8637501
Patent Number:	8629158
Patent Number:	8618299
Patent Number:	8710046
Patent Number:	8575114
Patent Number:	8802696
Patent Number:	7553846
Patent Number:	8278301
Patent Number:	8741901
Application Number:	11697415
Application Number:	12598882
Application Number:	14304833
Application Number:	13331814
Application Number:	13664546
Application Number:	13845919

Property Type	Number
Application Number:	13211678
Application Number:	13352864
Application Number:	12828955
Application Number:	12777728
Application Number:	13151992
Application Number:	62010799
Application Number:	14068470
Application Number:	61951123
Application Number:	14203033
Application Number:	14268753
Application Number:	14209460
Application Number:	14179845
Application Number:	12598912

#### CORRESPONDENCE DATA

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 212.318.6532

**Email:** alanagramer@paulhastings.com

**Correspondent Name:** ALANA GRAMER

**Address Line 1:** 200 PARK AVE, 28TH FLOOR

**Address Line 2:** C/O PAUL HASTINGS LLP

**Address Line 4:** NEW YORK, NEW YORK 10166

<b>ATTORNEY DOCKET NUMBER:</b>	CORRECTIVE TO 34045/951
<b>NAME OF SUBMITTER:</b>	ALANA GRAMER
<b>SIGNATURE:</b>	/Alana Gramer/
<b>DATE SIGNED:</b>	08/14/2018

**Total Attachments: 17**

source=assignment-pat-34045-951#page1.tif  
source=assignment-pat-34045-951#page2.tif  
source=assignment-pat-34045-951#page3.tif  
source=assignment-pat-34045-951#page4.tif  
source=assignment-pat-34045-951#page5.tif  
source=assignment-pat-34045-951#page6.tif  
source=assignment-pat-34045-951#page7.tif  
source=assignment-pat-34045-951#page8.tif  
source=assignment-pat-34045-951#page9.tif  
source=assignment-pat-34045-951#page10.tif  
source=assignment-pat-34045-951#page11.tif  
source=assignment-pat-34045-951#page12.tif

source=assignment-pat-34045-951#page13.tif  
source=assignment-pat-34045-951#page14.tif  
source=assignment-pat-34045-951#page15.tif  
source=assignment-pat-34045-951#page16.tif  
source=assignment-pat-34045-951#page17.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3080326

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ALBANY MOLECULAR RESEARCH, INC.	10/24/2014
ALO ACQUISITION LLC	10/24/2014
AMRI BURLINGTON, INC.	10/24/2014
AMRI RENSSELAER, INC.	10/24/2014
CEDARBURG PHARMACEUTICALS, INC.	10/24/2014
OSO BIOPHARMACEUTICALS MANUFACTURING, LLC	10/24/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
<b>Street Address:</b>	745 7TH AVENUE
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019
<b>PROPERTY NUMBERS Total: 103</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7238704
Patent Number:	7745619
Patent Number:	8053428
Patent Number:	7842802
Patent Number:	7235564
Patent Number:	7956050
Patent Number:	8039453
Patent Number:	8791101
Patent Number:	8106244
Patent Number:	8575186
Patent Number:	8268868
Patent Number:	7863271
Patent Number:	8716308
Patent Number:	8101632
Patent Number:	8124600
Patent Number:	8501729
<b>PATENT</b>	

Property Type	Number
Patent Number:	8710047
Patent Number:	7307094
Patent Number:	7781430
Patent Number:	8754054
Patent Number:	8697700
Patent Number:	6949559
Patent Number:	6747039
Patent Number:	7538084
Patent Number:	7084152
Patent Number:	6579885
Patent Number:	7612090
Patent Number:	7265116
Patent Number:	7419985
Patent Number:	7309789
Patent Number:	7541537 7541357 AB
Patent Number:	7799756
Patent Number:	7511013
Patent Number:	7378391
Patent Number:	7361636
Patent Number:	7632807
Patent Number:	8227486
Patent Number:	8236796
Patent Number:	8445494
Patent Number:	8420811
Patent Number:	5750703
Patent Number:	6444824
Patent Number:	6458958
Patent Number:	6919458
Patent Number:	7678915
Patent Number:	8476445
Patent Number:	6201124
Patent Number:	6452011
Patent Number:	6448406
Patent Number:	6974872
Patent Number:	7560561
Patent Number:	8022220
Patent Number:	6613907
Patent Number:	7232908
Patent Number:	7691615

PATENT

REEL: 046796 FRAME: 0358

Property Type	Number
Patent Number:	7863452
Patent Number:	8067605
Patent Number:	7858798
Patent Number:	8067604
Patent Number:	8178666
Patent Number:	6797826
Patent Number:	7238834
Patent Number:	7390906
Patent Number:	5578610
Patent Number:	5581011
Patent Number:	5589487
Patent Number:	5994549
Patent Number:	5663412
Patent Number:	6153754
Patent Number:	7163949
Patent Number:	7321064
Patent Number:	8183401
Patent Number:	8541609
Patent Number:	8110681
Patent Number:	8273770
Patent Number:	8637501
Patent Number:	8629158
Patent Number:	8618299
Patent Number:	8710046
Patent Number:	8575114
Patent Number:	8802696
Patent Number:	7553846
Patent Number:	8278301
Patent Number:	8741901
Application Number:	11697415
Application Number:	12598882
Application Number:	14304833
Application Number:	13331814
Application Number:	13664546
Application Number:	13845919
Application Number:	13211678
Application Number:	13352864
Application Number:	12828955
Application Number:	12777728

**PATENT**

**REEL. 036736 FRAME. 0959**



Property Type	Number
Application Number:	13151992
Application Number:	62010799
Application Number:	14068470
Application Number:	61951123
Application Number:	14203033
Application Number:	14268753
Application Number:	14209460
Application Number:	14179845
Application Number:	12598912

#### CORRESPONDENCE DATA

**Fax Number:** (212)303-7064

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 212.318.6824

**Email:** christinedionne@paulhastings.com

**Correspondent Name:** CHRISTINE DIONNE C/O PAUL HASTINGS LLP

**Address Line 1:** 75 EAST 55TH STREET

**Address Line 4:** NEW YORK, NEW YORK 10022

**ATTORNEY DOCKET NUMBER:** 91825.00018

**NAME OF SUBMITTER:** CHRISTINE DIONNE

**SIGNATURE:** /CHRISTINE DIONNE/

**DATE SIGNED:** 10/24/2014

#### Total Attachments: 13

source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page1.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page2.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page3.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page4.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page5.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page6.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page7.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page8.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page9.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page10.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page11.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page12.tif  
source=Barclays\_AMRI - Patent Security Agreement(112503731\_1) (2)#page13.tif

**PATENT SECURITY AGREEMENT**

**Patent Security Agreement**, dated as of October 24, 2014, by each of the parties listed on the signature pages hereto (each, a “Grantor”), in favor of BARCLAYS BANK PLC, in its capacity as collateral agent pursuant to the Credit Agreement (in such capacity, the “Collateral Agent”).

**WITNESSETH:**

WHEREAS, the Grantor is party to that certain Security Agreement dated as of October 24, 2014 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), by and among the Borrower, the other Grantors party thereto and the Collateral Agent, in favor of the Collateral Agent, pursuant to which the Grantor is required to execute and deliver to the Collateral Agent this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Collateral Agent, for the benefit of the Secured Parties, to enter into the Credit Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and with the intent to be legally bound hereby, the Grantor hereby agrees with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Credit Agreement or the Security Agreement and used herein have the respective meanings assigned thereto in the Credit Agreement or the Security Agreement, in each case, as applicable.

SECTION 2. Grant of Security Interest in Patent Collateral. The Grantor hereby pledges and grants to the Collateral Agent for the benefit of the Secured Parties a lien on and security interest in and to all of its right, title and interest in, to and under all the following Collateral of the Grantor:

- (a) all Patents of the Grantor listed on Schedule I attached hereto; and
- (b) all products and Proceeds of any of the foregoing (together with (a), collectively, the “Patents”).

SECTION 3. The Security Agreement. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to the Collateral Agent pursuant to the Security Agreement, and the Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the security interests in the Patents made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Termination. Upon the termination of the Security Agreement in accordance with, or as otherwise required pursuant to, Section 6.12 thereof, the Collateral Agent shall, at the expense of the Grantor, execute, acknowledge, and deliver to the Grantor an instrument in writing in recordable form releasing the liens on and security interests in the applicable Patents under this Patent Security Agreement and any other documents required to evidence the termination of the Collateral Agent’s interests in the applicable Patents.

**SECTION 5. GOVERNING LAW; JURISDICTION; VENUE; WAIVER OF JURY TRIAL; CONSENT TO SERVICE OF PROCESS.**

(A) THE TERMS OF SECTION 10.13 OF THE CREDIT AGREEMENT WITH RESPECT TO GOVERNING LAW, SUBMISSION OF JURISDICTION, VENUE AND WAIVER OF JURY TRIAL ARE INCORPORATED HEREIN BY REFERENCE, *MUTATIS MUTANDIS*, AND THE PARTIES HERETO AGREE TO SUCH TERMS.

(B) EACH PARTY TO THIS PATENT SECURITY AGREEMENT IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 6.01 OF THE SECURITY AGREEMENT. NOTHING IN THIS PATENT SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS PATENT SECURITY AGREEMENT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

SECTION 6. Waivers; Amendments; Modifications. Neither this Patent Security Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Collateral Agent and the Grantor or Grantors with respect to which such waiver, amendment or modification is to apply, subject to any consent required in accordance with Section 10.01 of the Credit Agreement and subject to Section 6.02 of the Security Agreement.


SECTION 7. Notices; Communications. All communications and notices under this Patent Security Agreement shall be in writing and given as provided in Section 6.01 of the Security Agreement.

SECTION 8. Counterparts; Effectiveness. This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Patent Security Agreement by signing and delivering to the other party hereto one or more counterparts. Delivery by facsimile or other electronic communication of an executed counterpart (including portable document format (PDF)) of a signature page to this Patent Security Agreement shall be effective as delivery of an original executed counterpart of this Patent Security Agreement. This Patent Security Agreement shall become effective as to the Grantor when a counterpart hereof executed on behalf of the Grantor shall have been delivered to the Collateral Agent and a counterpart hereof shall have been executed on behalf of the Collateral Agent, and thereafter shall be binding upon the Grantor and the Collateral Agent and their respective permitted successors and assigns, and shall inure to the benefit of the Grantor, the Collateral Agent and the other Secured Parties and their respective permitted successors and assigns, except that the Grantor shall not have the right to assign or transfer its rights or obligations hereunder or any interest herein or in the Collateral (and any such assignment or transfer shall be void) except as expressly contemplated by the Security Agreement or the Credit Agreement.


[Signature Pages Follow]

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be duly executed and delivered as of the date first above written.


**ALBANY MOLECULAR RESEARCH,  
INC., as a Grantor**

By:   
Name: Michael M. Nolan  
Title: Chief Financial Officer


**ALO ACQUISITION LLC, as a Grantor**

By:   
Name: Michael M. Nolan  
Title: Chief Financial Officer


**AMRI BURLINGTON, INC., as a Grantor**

By:   
Name: Michael M. Nolan  
Title: Chief Financial Officer


**AMRI RENSSELAER, INC., as a Grantor**

By:   
Name: Michael M. Nolan  
Title: Chief Financial Officer

**CEDARBURG PHARMACEUTICALS,  
INC., as a Grantor**


By:   
Name: Michael M. Nolan  
Title: Chief Financial Officer

**OSO BIOPHARMACEUTICALS  
MANUFACTURING, LLC, as a Grantor**

By:   
Name: Michael M. Nolan  
Title: Chief Financial Officer

ACCEPTED AND AGREED  
as of the date first above written:

**BARCLAYS BANK PLC**, as the Collateral Agent

By:   
Name: Ann E. Sutton  
Title: Director

**Schedule I**  
**to**  
**PATENT SECURITY AGREEMENT**  
**UNITED STATES PATENTS AND PATENT APPLICATIONS**

**Patents:**

<b>OWNER</b>	<b>PATENT NUMBER</b>	<b>TITLE</b>
Albany Molecular Research, Inc.	7,238,704	VINCA DERIVATIVES
Albany Molecular Research, Inc.	7,745,619	VINCA DERIVATIVES
Albany Molecular Research, Inc.	8,053,428	VINORELBINE DERIVATIVES
Albany Molecular Research, Inc.	7,842,802	VINORELBINE DERIVATIVES
Albany Molecular Research, Inc.	7,235,564	VINORELBINE DERIVATIVES
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	7,956,050	ARYL- AND HETEROARYL- SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc.	8,039,453	VINCA DERIVATIVES
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,791,101	ARYL- AND HETEROARYL- SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc.	8,106,244	PROCESS FOR PRODUCTION OF DELTA-9- TETRAHYDROCANNABINOL
Albany Molecular Research, Inc.	8,575,186	EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT <sub>6</sub> ) MODULATORS AND USES THEREOF
Albany Molecular Research, Inc.	8,268,868	5-PYRIDINONE SUBSTITUTED INDAZOLES
Albany Molecular Research, Inc.	7,863,271	2-AMINO BENZOXAZOLE CARBOXAMIDES AS 5HT <sub>3</sub> MODULATORS

Albany Molecular Research, Inc.	8,716,308	(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES
Albany Molecular Research, Inc.	8,101,632	5-FUROPYRIDINONE SUBSTITUTED INDAZOLES
Albany Molecular Research, Inc.	8,124,600	5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	8,501,729	5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	8,710,047	5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	7,307,094	BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D
Albany Molecular Research, Inc.	7,781,430	BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D
Albany Molecular Research, Inc.	8,754,054	ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF
Albany Molecular Research, Inc.	8,697,700	PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF
Albany Molecular Research, Inc.	6,949,559	NITROGEN SUBSTITUTED BIARYL PURINE DERIVATIVES AS POTENT ANTIPROLIFERATIVE AGENTS
Albany Molecular Research, Inc.	6,747,039	AZA-BENZOTHIOPYRANOINDAZOLES WITH ANTITUMOR ACTIVITY
Albany Molecular Research, Inc.	7,538,084	CYCLOSPORINS
Albany Molecular Research, Inc.	7,084,152	NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES THERAPEUTIC USE THEREOF
Albany Molecular Research, Inc.	6,579,885	ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF
Albany Molecular Research, Inc.	7,612,090	ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF
Albany Molecular Research, Inc.	7,265,116	ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES

		AND USE THEREOF
Albany Molecular Research, Inc.	7,419,985	4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF
Albany Molecular Research, Inc.	7,309,789	NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	7,541,357	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc.	7,799,756	NOVEL PROCESSES FOR STEREOSELECTIVE SYNTHESIS OF TRANS ISATx247
Albany Molecular Research, Inc.	7,511,013	NOVEL CYCLOSPORIN ANALOGUES AND THEIR PHARMACEUTICAL USES
Albany Molecular Research, Inc.	7,378,391	CYCLOSPORIN ALKYNE ANALOGUES AND THEIR PHARMACEUTICAL USES
Albany Molecular Research, Inc.	7,361,636	NOVEL CYCLOSPORIN ALKYNES AND THEIR UTILITY AS PHARMACEUTICAL AGENTS
Albany Molecular Research, Inc.	7,632,807	NOVEL CYCLOSPORIN ALKYNES AND THEIR UTILITY AS PHARMACEUTICAL AGENTS
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,227,486	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,236,796	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,445,494	CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZINE-3-AMINE



Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,420,811	TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR
Albany Molecular Research, Inc.	5,750,703	PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	6,444,824	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,458,958	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,919,458 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	7,678,915 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	8,476,445 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,201,124	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,452,011	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,448,406	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,974,872 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	7,560,561 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	8,022,220 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,613,907	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS
Albany Molecular Research, Inc.	7,232,908 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS
Albany Molecular Research, Inc.	7,691,615 B2	PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS
Albany Molecular Research, Inc.	7,863,452 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	8,067,605 B2	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	7,858,798 B2	PROCESS FOR PRODUCTION OF CAREBASTINE
Albany Molecular Research, Inc.	8,067,604 B2	PROCESS FOR PRODUCTION OF CAREBASTINE
Albany Molecular Research, Inc.	8,178,666 B2	2-AMINO BENZOXAZOLE PROCESS

Albany Molecular Research, Inc.	6,797,826	PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	7,238,834	PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	7,390,906	PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	5,578,610	PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	5,581,011	AROMATIC KETONES AND PROCESSES FOR THEIR PREPARATION
Albany Molecular Research, Inc.	5,589,487	PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	5,994,549	PIPERDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	5,663,412	AROMATIC KETONES
Albany Molecular Research, Inc.	6,153,754	PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES
Albany Molecular Research, Inc.	6,797,826	PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
Albany Molecular Research, Inc.	7,163,949	4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF
Cedarburg Pharmaceuticals, Inc.	7,321,064	PREPARATION OF AMIDES OF RETINOIC ACID VIA MIXED ANHYDRIDE AND MIXED CARBONATE INTERMEDIATES
Cedarburg Pharmaceuticals, Inc.	8,183,401	EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME
Cedarburg Pharmaceuticals, Inc.	8,541,609	EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME
Albany Molecular Research, Inc. and The United States of America, as represented by the Secretary, Department of Health and Human Services	8,110,681	COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES
Albany Molecular Research, Inc.	8,273,770	5-PYRIDINONE SUBSTITUTED INDAZOLES

Albany Molecular Research, Inc.	8,637,501	AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	8,629,158	AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	8,618,299	AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	8,710,046	5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	8,575,114	SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,802,696	7-([1,2,4]TRIAZOLO[1,5-a]PYRIDINYL-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
Albany Molecular Research, Inc.	7,553,846	2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS
Albany Molecular Research, Inc.	8,278,301	2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	8,741,901	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN

**Patent Applications:**

OWNER	APPLICATION NUMBER	TITLE
Albany Molecular Research, Inc.	11/697,415	VINCA DERIVATIVES
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	12/598,882	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN
Albany Molecular Research, Inc. and Bristol Myers Squibb Company	12/598,912	ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	14/304,833	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc.	13/331,814	TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	13/664,546	PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	13/845,919	CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZINE-3-AMINE
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	13/211,678	2,5-METHANO- and 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE,

		DOPAMINE, AND SEROTONIN
Albany Molecular Research, Inc.	13/352,864	BENZOFURO[3,2-C] PYRIDINE AND AZEPINE ANALOGS AS SEROTONIN SUB TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA
Albany Molecular Research, Inc.	12/828,955	AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc.	12/777,728	ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF
Albany Molecular Research, Inc.	13/151,992	GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF
Albany Molecular Research, Inc.	62/010,799	GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF
Albany Molecular Research, Inc.	14/068,470	PYRIDO-/AZEPINO-BENZOFURAN AND PYRIDO-/AZEPINO-BENZOTHIPIHENE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	61/951,123	NOVEL TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN
Albany Molecular Research, Inc.	14/203,033	5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF

Albany Molecular Research, Inc. and Bristol-Myers Squibb Company	14/268,753	ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN
Albany Molecular Research, Inc.	14/209,460	LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM
Albany Molecular Research, Inc.	14/179,845	NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF